SOAT1 and Alzheimer disease: The JAK-STAT pathway is a key signaling pathway in the development of AD and AA, and JAK inhibitors have shown promising therapeutic efficacy by blocking the signaling of key cytokines in this pathway and suppressing inflammatory responses (121, 122).